Here, we find that targeting DDX11, a gene whose up-regulation in several cancers correlates with poor patient prognosis (9, –11), sensitizes ovarian, uterine, and other cancers to PARP inhibitors and platinum chemotherapies by causing an accumulation of DNA damage and mitotic instability. This evidence concerns the gene PARP1 and cancer.